This study raises concerns about the Bmi1 inhibitors that are currently under clinical trials (for diseases including glioblastoma multiforme (GBM), colorectal cancer, head neck squamous cell carcinoma) and suggests a closer look for adverse side effects [88]. Here, BMI1 is linked to glioblastoma.